Compare BioNTech SE - ADR (BNTX) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs FedEx Corporation — how do they compare? BioNTech SE - ADR trades at $92.46 (market cap $23.30B), while FedEx Corporation trades at $338.67 (market cap $77.31B). The key difference: FedEx Corporation is far larger — about 3.3× BioNTech SE - ADR's market cap, and FedEx Corporation pays a 1.49% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | FDX | |
|---|---|---|
Market Cap | $23.30B | $77.31B |
Sector | Health | Industrials |
52-Week High | $119.34 | $338.75 |
52-Week Low | $83.89 | $180.51 |
Enterprise Value | $6.60B | $106.94B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.12, down 0.73% on the day, amid weak COVID-19 vaccine demand and a net loss of $1.14 billion in 2025. The stock shows a bullish technical signal with support near $92 and resistance at $93, while fundamentals reveal a high P/E of 161.14 and negative profitability margins. Recent news highlights a CEO transition to Guido Oelkers and a lowered 2026 sales outlook due to softening vaccine revenue.
The outlook remains cautious with declining revenues and persistent losses, though a strong cash position of $16.78 billion supports its oncology pipeline development. Risks include execution challenges in shifting from COVID-19 dependence, while analyst consensus is bullish with a $121 price target, implying 31% upside from current levels.
FedEx (FDX) trades at $339.35, up 5.25% with a bullish technical signal. Recent earnings beat expectations, with Q1 2026 EPS of $6.31 versus $5.96 expected. The company maintains solid fundamentals, including a P/E of 17.62 and net income margin of 4.68%, while executing a strategic pivot to premium services and cost optimization under its Network 2.0 initiative targeting $2 billion in annual savings.
Outlook is positive with analyst consensus at Buy (57% of ratings) and a $360.27 price target, though risks include competitive pressures and macroeconomic sensitivity. The stock offers value with reasonable valuation and dividend yield, supported by strong institutional interest and operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
